Can I Take Calcium With Brisdelle (Paroxetine 7.5 mg)?

The Short Answer: Calcium and Brisdelle Are Generally Compatible

No major pharmacokinetic clash exists between calcium supplements and paroxetine 7.5 mg. The FDA prescribing information for Brisdelle does not list calcium as a contraindicated or interacting co-medication. Still, two indirect concerns deserve your attention: calcium's well-documented ability to interfere with the absorption of other drugs taken at the same time, and the broader cardiovascular conversation around calcium supplementation in postmenopausal women.

Understanding both issues helps you take these two safely together, without guessing.

What Is Brisdelle and Why Do Postmenopausal Women Use It?

Brisdelle is a low-dose, non-hormonal prescription option for moderate-to-severe menopausal vasomotor symptoms (hot flashes and night sweats). It contains paroxetine 7.5 mg, making it the only FDA-approved non-hormonal treatment specifically indicated for this purpose at the time of its 2013 approval. Standard antidepressant doses of paroxetine run 20 to 60 mg per day, so the Brisdelle dose is deliberately sub-therapeutic for depression, which changes its side-effect profile and drug-interaction risk compared with higher doses.

The Menopause Society (formerly NAMS) 2023 Position Statement on nonhormone therapies assigns paroxetine mesylate a Level I evidence rating for hot flash reduction, noting a roughly 33 to 65 percent decrease in hot flash frequency in clinical trials. That evidence base is drawn almost entirely from women, which is worth acknowledging as a meaningful data strength.

Why Calcium Comes Up in This Conversation

Postmenopausal women lose bone at an accelerated rate once estrogen levels fall. The National Osteoporosis Foundation, now the Bone Health and Osteoporosis Foundation, recommends 1,200 mg of calcium per day for women over 50, with a preference for dietary sources first and supplementation used to fill the gap. Many women on Brisdelle are therefore also taking a calcium supplement, a bisphosphonate, or both.

Pharmacokinetics: Does Calcium Actually Affect Paroxetine Absorption?

The direct answer is probably not, but the mechanism of concern is worth knowing.

How Paroxetine Is Absorbed

Paroxetine is absorbed via passive diffusion in the gastrointestinal tract and does not rely on divalent cation transporters the way tetracycline antibiotics or thyroid hormone do. Paroxetine reaches peak plasma concentration (Tmax) in approximately 5 hours and undergoes extensive first-pass hepatic metabolism via CYP2D6. Calcium ions do not inhibit or induce CYP2D6, so the major metabolic pathway is unaffected.

No peer-reviewed pharmacokinetic study has specifically tested calcium co-administration with paroxetine 7.5 mg. That data gap matters and deserves naming: the interaction assumption is extrapolated from general principles of divalent-cation chelation chemistry, not from a dedicated paroxetine-calcium PK trial.

Where Calcium Can Cause Trouble With Other Drugs You May Be Taking

The interaction concern becomes concrete when you zoom out to your full medication list. Calcium carbonate in particular:

• Reduces levothyroxine absorption by up to 39 percent if taken simultaneously, relevant if you have hypothyroidism and are managing both conditions alongside menopause.
• Significantly reduces the bioavailability of oral bisphosphonates such as alendronate. Alendronate bioavailability falls by approximately 60 percent when co-administered with calcium, which is why you are instructed to take alendronate first thing in the morning on an empty stomach.
• May reduce the absorption of some fluoroquinolone antibiotics and iron supplements when taken at the same time.

The lesson: the Brisdelle-calcium pairing itself is low concern, but if you also take levothyroxine or a bisphosphonate, your scheduling across all three drugs becomes genuinely important.

Calcium Citrate vs. Calcium Carbonate: Does the Form Matter?

Yes, and specifically for you if your stomach acid production is reduced (common in older postmenopausal women or those on proton pump inhibitors). Calcium carbonate requires stomach acid for dissolution and absorption. Calcium citrate does not. Calcium citrate is better absorbed in low-acid states and causes less constipation. If Brisdelle's mild GI side effects (nausea affects roughly 4 percent of users in trials) overlap with your calcium timing, switching to calcium citrate and taking it with food reduces GI burden without affecting paroxetine exposure.

Pharmacodynamics: Are There Any Combined Effects to Watch?

Pharmacodynamically, calcium and paroxetine work in entirely separate biological systems. Paroxetine inhibits the serotonin transporter (SERT), reducing serotonin reuptake and thereby modulating the thermoregulatory signaling in the hypothalamus that drives hot flashes. Calcium acts on bone mineralization, neuromuscular function, and cardiac conduction. No shared receptor or transporter pathway creates a pharmacodynamic interaction.

One indirect area worth monitoring: paroxetine at any dose can cause mild QTc prolongation in susceptible individuals, though the signal at 7.5 mg is far weaker than at antidepressant doses. Hypercalcemia shortens the QT interval. These opposing effects on cardiac conduction mean that in the unusual scenario where you develop hypercalcemia (from excessive supplementation or an underlying condition such as primary hyperparathyroidism, which is more common in postmenopausal women), your overall cardiac electrophysiology becomes slightly harder to predict. This is not a reason to avoid calcium at recommended doses. It is a reason to stay within the evidence-based upper tolerable intake level of 2,500 mg per day for women ages 19 to 50 and 2,000 mg per day for women over 50.

The Cardiovascular Calcium Debate: What Postmenopausal Women on Brisdelle Need to Know

Since roughly 2010, a series of meta-analyses has raised questions about whether supplemental calcium increases cardiovascular event risk in postmenopausal women. The most cited is the Bolland et al. 2011 meta-analysis in the BMJ, which reported a hazard ratio of 1.27 for myocardial infarction with calcium supplementation alone (without vitamin D). This analysis has been contested on methodological grounds, and subsequent re-analyses of the Women's Health Initiative data did not confirm the risk in women who were not already supplementing at baseline.

The 2022 USPSTF statement on vitamin D and calcium for primary prevention of cancer and cardiovascular disease concluded that evidence was insufficient to assess the cardiovascular benefits and harms of supplemental calcium in postmenopausal women specifically for CVD prevention.

What does this mean for you on Brisdelle? Brisdelle is not cardioprotective or cardiotoxic at 7.5 mg in any demonstrated way. The cardiovascular calcium question stands independent of paroxetine. If your clinician has already reviewed your cardiovascular risk profile and advised calcium, that recommendation holds. If you are self-supplementing at doses above 1,000 mg per day without a dietary gap to fill, that dose is worth revisiting with your provider.

Life-Stage Guide: How This Changes Across Reproductive Years

Brisdelle is indicated for menopausal vasomotor symptoms, so the primary population is perimenopausal and postmenopausal women. The calcium interaction question, though, has distinct answers depending on where you are in your hormonal life.

Perimenopause (Typically Ages 45 to 55)

Vasomotor symptoms often begin while cycles are still irregular. Estrogen is fluctuating, not absent. Bone loss is already accelerating at this stage, with women losing up to 2 to 3 percent of bone mineral density per year in the first few years after menopause. Calcium needs shift upward. If Brisdelle is prescribed during this transition, both the drug and the supplement are appropriate co-management tools. The RDA for calcium during perimenopause (age 51 onward) is 1,200 mg daily.

Postmenopause

This is the target life stage for Brisdelle's indication. Hot flashes can persist for a median of 7 years after the final menstrual period, and approximately 25 to 30 percent of women still experience clinically significant vasomotor symptoms 10 or more years after menopause. Calcium supplementation at this stage is often paired with vitamin D (800 to 1,000 IU daily is a common clinician recommendation), bisphosphonates if osteoporosis is present, and sometimes hormone therapy if Brisdelle alone is insufficient for symptom control.

Reproductive Years (If Brisdelle Is Prescribed Off-Label)

Brisdelle is not approved for depression or anxiety in reproductive-aged women. If a clinician is prescribing paroxetine at any dose to a woman who could become pregnant, the contraception discussion is mandatory. Calcium at the RDA of 1,000 mg for women aged 19 to 50 is safe and important during the reproductive years.

Pregnancy and Lactation: Essential Safety Information

Brisdelle is contraindicated in pregnancy. This is a non-negotiable safety point.

Pregnancy

Paroxetine carries FDA Pregnancy Category D designation based on epidemiological data linking first-trimester paroxetine exposure to a small but measurable increase in congenital cardiac malformations, particularly ventricular septal defects. The absolute risk increase is small, but paroxetine consistently shows a worse fetal safety profile among SSRIs. The Brisdelle prescribing information explicitly states the drug should be discontinued if pregnancy is discovered.

ACOG Practice Bulletin on Perinatal Depression notes that if an antidepressant must be continued in pregnancy, paroxetine requires a careful individualized risk discussion, and switching to an alternative with a better pregnancy safety profile (such as sertraline) is often preferred.

Women who retain any possibility of pregnancy while on Brisdelle should use reliable contraception. The drug's sub-antidepressant dose does not reduce this requirement.

Calcium during pregnancy is not just safe, it is necessary. The RDA rises to 1,000 mg per day during pregnancy (unchanged from non-pregnant adults, because intestinal calcium absorption efficiency increases), but adequate intake is critical for fetal skeletal development and reducing the risk of gestational hypertension and preeclampsia, where calcium supplementation at 1,500 to 2,000 mg has shown benefit in low-intake populations.

Lactation

Paroxetine passes into human breast milk at low levels. A 2001 review in the American Journal of Psychiatry found that infant plasma paroxetine levels were generally undetectable in breastfed infants of mothers taking paroxetine, though monitoring for infant irritability and feeding changes is still advised. Brisdelle's labeling advises caution during breastfeeding given limited data at the 7.5 mg dose specifically.

Calcium supplementation during lactation is considered safe and recommended. Breastfeeding women need 1,000 mg of calcium daily, with the understanding that maternal bone loss during lactation (1 to 3 percent at the spine) typically reverses after weaning.

Who This Is Right For and Who Should Reconsider

Women Who Are Good Candidates for Both

• Postmenopausal women with moderate-to-severe hot flashes who cannot or prefer not to use hormone therapy, combined with a dietary calcium gap below the 1,200 mg daily target.
• Women with PCOS who have entered perimenopause and have established insulin resistance, since paroxetine at vasomotor-symptom doses does not worsen insulin sensitivity in the way some other psychotropics might.
• Women with a history of estrogen-receptor-positive breast cancer, for whom hormone therapy is often contraindicated. The Menopause Society 2023 statement specifically lists paroxetine mesylate as a preferred nonhormone option in breast cancer survivors, with the caveat below.

Women Who Need Extra Caution

• Women taking tamoxifen for breast cancer treatment. Paroxetine is a potent CYP2D6 inhibitor even at low doses. Tamoxifen requires CYP2D6 conversion to its active metabolite endoxifen. Co-prescription meaningfully reduces endoxifen levels and may reduce tamoxifen's protective effect. A retrospective cohort study published in the BMJ estimated that concurrent use of paroxetine and tamoxifen was associated with a 25 percent increase in breast cancer mortality at 2-year co-prescription overlap. Calcium has no effect on this interaction, but women on tamoxifen should choose a different SSRI for hot flash management.
• Women with hypercalcemia from any cause (hyperparathyroidism, sarcoidosis, excessive vitamin D). Adding a calcium supplement in this context is inappropriate regardless of Brisdelle.
• Women with a history of kidney stones, particularly calcium oxalate stones. Supplemental calcium above dietary needs may increase stone recurrence risk in susceptible women.

Practical Dosing Schedule: How to Time Everything

Here is a sample daily schedule for a postmenopausal woman taking Brisdelle 7.5 mg, calcium 600 mg twice daily, and levothyroxine.

| Time | What to Take | Notes | |---|---|---| | 6:00 AM (empty stomach) | Levothyroxine | No food, coffee, or calcium for 30-60 min | | 7:00 AM (with breakfast) | Calcium 600 mg (citrate preferred) | Food improves GI tolerance | | 10:00 PM (with evening snack) | Brisdelle 7.5 mg + calcium 600 mg | Manufacturer advises bedtime dosing; calcium is fine here |

If you are also on a weekly bisphosphonate (alendronate or risedronate), take it on your scheduled day first thing in the morning, wait at least 30 minutes before eating, and delay calcium by a full two hours. Brisdelle at bedtime on that same day poses no scheduling conflict.

Monitoring: What to Watch For

You do not need special lab monitoring solely because you are taking calcium and Brisdelle together. Standard monitoring for each independently applies.

For Brisdelle: Your clinician should assess hot flash frequency and severity at 4 to 8 weeks. If symptoms are not reduced by at least 50 percent, dose adjustment or a different approach is warranted. Blood pressure and mood should be reviewed at each visit, given paroxetine's class effects.

For calcium supplementation: Annual serum calcium and 25-hydroxyvitamin D are reasonable if you are taking both a calcium supplement and vitamin D. If your total daily calcium intake from diet and supplements consistently exceeds 2,000 mg, request a check of serum calcium and renal function to rule out early hypercalcemia. Bone density (DEXA scan) every one to two years is appropriate for postmenopausal women with osteoporosis risk factors, regardless of which medication you are on for hot flashes.

What the Evidence Gap Looks Like

No dedicated clinical trial has studied the combined use of calcium supplementation and paroxetine 7.5 mg in postmenopausal women. The Brisdelle key trials, including the Phase 3 trial published in Menopause (Pinkerton et al., 2013), did not systematically collect or report calcium supplement use as a variable. The absence of a documented interaction is reassuring but is not the same as a rigorously studied finding.

Women represent the entirety of the study population for this specific indication, which is a rare data strength. The pharmacokinetic question of calcium-paroxetine coadministration, however, has not been formally investigated. The two-hour separation window recommended here is based on calcium's known chelation chemistry with other drugs and is a precautionary extrapolation, not a finding proven in a paroxetine-specific trial.

Key Takeaways in Plain Language

Calcium and Brisdelle are compatible. Separate them by two hours if you take calcium carbonate. Calcium citrate is a gentler option if GI symptoms are a concern. Your total calcium from food and supplements should stay at or below 2,000 mg per day after age 50. If you also take levothyroxine or a bisphosphonate, their scheduling demands are stricter than Brisdelle's. Women on tamoxifen should not use paroxetine at any dose without a direct conversation with their oncologist about CYP2D6 consequences. Brisdelle must be stopped if you become pregnant, and reliable contraception is required throughout treatment.